文献速递血液净化与透析

血液透析通路血流监测与标准治疗的多中心随机对照试验:HASE 研究

A Multicenter Randomized Clinical Trial of Hemodialysis Access Blood Flow Surveillance Compared to Standard of Care: The Hemodialysis Access Surveillance Evaluation (HASE) Study.
PubMed 文献 · Kidney Int Rep · 2020-08-04

多中心前瞻性随机对照试验纳入 436 例血液透析的终末期肾病患者,比较每月超声稀释技术(UDT)血流监测联合标准治疗与单独标准治疗。监测组每患者血栓事件率显著低于对照组(0.12 vs 0.23/患者,P=0.012),但总操作次数、首次血栓事件率或时间、因血栓置管数无显著差异。

要点

  • 每月 UDT 血流监测可降低每患者血栓事件率,不增加总血管造影操作次数。
  • 监测未显著降低首次血栓事件率或延迟首次血栓事件时间。
  • 两组因血栓置管数无显著差异,监测的临床净获益需个体化权衡。

核心结论

  • 每月 UDT 血流监测联合标准治疗可显著减少每患者血栓事件,但不显著增加总操作次数。
  • 监测未显著降低首次血栓事件率或时间,也未减少因血栓置管数。

研究设计与样本

  • 多中心、前瞻性、随机对照试验,采用整群(班次)随机化。
  • 纳入 436 例血液透析的终末期肾病患者,血管通路为自体动静脉内瘘或人工血管。
  • 比较每月 UDT 血流监测联合标准治疗与单独标准治疗,平均随访 15.2 个月。

主要发现

  • 监测组每患者血栓事件率(Poisson 率)为 0.12/患者,对照组为 0.23/患者(P=0.012)。
  • 两组总操作次数(无论是否纳入血栓切除操作)无统计学显著差异。
  • 两组首次血栓事件率或时间、因血栓置管数无统计学显著差异。
  • 基线人口学数据除种族外(P=0.017)无显著差异。

临床怎么用

  • 对血液透析 AVF/AVG 患者可考虑每月 UDT 血流监测以降低血栓事件率。
  • 需向患者说明监测未显著降低首次血栓事件率,且不增加总操作次数。

局限性

  • 采用整群随机化,基线种族存在组间差异(P=0.017)。
  • 随访时间有限(平均 15.2 个月),未报告盲法及样本量计算细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Arteriovenous (AV) access thrombosis remains 1 of the most troubling AV access-related complications affecting hemodialysis patients. It necessitates an urgent and occasionally complicated thrombectomy procedure and increases the risk of AV access loss. AV access stenosis is found in the majority of thrombosed AV accesses. The routine use of AV access surveillance for the early detection and management of stenosis to reduce the thrombosis rate remains controversial. METHODS: We have conducted a multicenter, prospective, randomized clinical trial comparing the standard of care coupled with ultrasound dilution technique (UDT) flow measurement monthly surveillance with the standard of care alone. RESULTS: We prospectively randomized 436 patients with end-stage renal disease on hemodialysis with arteriovenous fistula (AVF) or arteriovenous graft (AVG) using cluster (shift) randomization to surveillance and control groups. There were no significant differences in the baseline demographic data between the 2 groups, except for ethnicity (P = 0.017). Patients were followed on average for 15.2 months. There were significantly less per-patient thrombotic events (Poisson rate) in the surveillance group (0.12/patient) compared with the control group (0.23/patient) (P = 0.012). There was no statistically significant difference in the total number of procedures between the 2 groups, irrespective of whether thrombectomy procedures were included or excluded, and no statistically significant differences in the rate of or time to the first thrombotic event or the number of catheters placed due to thrombosis. CONCLUSION: The use of UDT flow measurement monthly AV access surveillance in this multicenter randomized controlled trial reduced the per-patient thrombotic events without significantly increasing the total number of angiographic procedures. Even though there is a trend, surveillance did not reduce the first thrombotic event rate.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Salman L, Rizvi A, Contreras G, et al. A Multicenter Randomized Clinical Trial of Hemodialysis Access Blood Flow Surveillance Compared to Standard of Care: The Hemodialysis Access Surveillance Evaluation (HASE) Study. Kidney Int Rep. 2020. PMID: 33163714. doi:10.1016/j.ekir.2020.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。